Index Entries

SARS-CoV-2 Vaccination and Myocarditis in a Nordic Cohort Study of 23 Million Residents

https://jamanetwork.com/journals/jamacardiology/fullarticle/2791253 

Øystein Karlstad, Petteri Hovi, Anders Husby, Tommi Härkänen, Randi Marie Selmer, Nicklas Pihlström, Jørgen Vinsløv Hansen, Hanna Nohynek, Nina Gunnes, Anders Sundström, Jan Wohlfahrt, Tuomo A. Nieminen, Maria Grünewald, Hanne Løvdal Gulseth, Anders Hviid, and Rickard Ljung
April 20, 2022
JAMA Cardiology
Norwegian Institute of Public Health

“Question: Is SARS-CoV-2 messenger RNA (mRNA) vaccination associated with risk of myocarditis?

Findings: In a cohort study of 23.1 million residents across 4 Nordic countries, risk of myocarditis after the first and second doses of SARS-CoV-2 mRNA vaccines was highest in young males aged 16 to 24 years after the second dose. For young males receiving 2 doses of the same vaccine, data were compatible with between 4 and 7 excess events in 28 days per 100 000 vaccinees after second-dose BNT162b2, and between 9 and 28 per 100 000 vaccinees after second-dose mRNA-1273.”

This is an open access article distributed under the terms of the CC-BY License.© 2022 Karlstad Ø et al. JAMA Cardiology.

document
adverse events,COVID-19,heart disorders,vaccines